Source BioScience reports strong Q3
Diagnostics and genetic analysis business Source BioScience said a good performance in the third quarter meant it was on track to meet full year expectations.
Diagnostics and genetic analysis business Source BioScience said a good performance in the third quarter meant it was on track to meet full year expectations.
The company said the three months to the end of September had been a period of sustained growth and
development with increased revenue in both its LifeSciences and Healthcare divisions.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The performance was underpinned by growth in the firm's cytology business (which studies cell structure), driven by the adoption of automated imaging for cervical cancer screening.
The LifeSciences division also took increasing market share for DNA sequencing in the UK.
Source said it was in a robust financial position with £2m cash as of September 30th, up from £1.8m at the end of June.
MM
-
4 tax tips for the Bank of Mum and Dad before the end of the tax year
Parents and grandparents wishing to gift money in a tax-efficient way need to be aware of the looming 5 April end-of-tax year deadline. Here are our tips to beat the deadline.
By Ruth Emery Published
-
What can we expect from the NS&I British Savings Bond?
NS&I’s new British Savings Bond will launch next month. What will it look like, what sort of interest rate could it pay, and how will it compare to the rest of the savings market?
By Vaishali Varu Published